Results 171 to 180 of about 1,345,578 (303)

Network Localization of Fatigue in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo   +12 more
wiley   +1 more source

Vitamin B12-peptide nucleic acids use the BtuB receptor to pass through the Escherichia coli outer membrane. [PDF]

open access: yesBiophys J, 2021
Pieńko T   +7 more
europepmc   +1 more source

The Monetary Transmission Mechanism in The United Kingdom: Pass-Through & Policy Ru [PDF]

open access: yes
A number of recent papers have used policy simulations from small empirical macro models to assess the efficacy of inflation-forecast targeting. The macro models used to undertake the simulations differ significantly with the assumed degree of openness ...
Alastair Cunningham, Andrew G. Haldane
core  

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks   +10 more
wiley   +1 more source

Convergence of Monetary Transmission in EMU New Evidence [PDF]

open access: yes
This paper examines how the pass-through of monetary policy measures in 6 EMU countries has evolved over time and whether there is convergence in monetary transmission.
Jakob de Haan   +2 more
core  

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy